Globus Medical Inc (GMED) Stock Analysis and Metrics

Globus Medical

NYSE: GMED

$76.45 ▲ +1.03 (+1.37%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap10.21 Bn

P/E17.40

P/S3.29

Div. Yield0.00

Revenue Growth (1y) (Qtr)27.04

Add ratio to table…

About

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The firm is dedicated to improving patient quality of life through innovative products and surgeon focused development. It maintains an engineering driven culture that enables rapid introduction of new technologies. Globus Medical, Inc. offers a broad portfolio spanning implantable devices, biologics, surgical instruments, spinal cord stimulation systems, neuromonitoring services and enabling technologies such as imaging navigation and robotics platforms. The company operates in over 65 countries and launched 9 new products in 2025.

The company generates revenue primarily through the sale of its medical devices and related services to hospitals ambulatory surgery centers and physicians. Sales are conducted via a direct sales force and through exclusive independent distributors who receive a commission based on a percentage of sales. Revenue streams include product sales of implantable devices biologics spinal cord stimulation systems and neuromonitoring services as well as service income from equipment leasing and technician support. In the year ended December 31 2025 international sales represented approximately 19.4% of total revenue while the remainder came from the United States.

The company operates through the following segments.

• Musculoskeletal Solutions: This segment includes implantable devices for spinal orthopedic and neurosurgical procedures such as pedicle screw systems interbody spacers and vertebral body replacement options. It also provides biologics including allografts and synthetic bone graft substitutes that are used alongside hardware to promote fusion. Additionally the segment offers surgical instruments spinal cord stimulation systems for chronic pain management and neuromonitoring services that assist surgeons during operations.

• Enabling Technologies: This segment comprises imaging navigation and robotics systems such as the ExcelsiusGPS robotic guidance platform which supports minimally invasive and open screw placement. It also includes the Surgimap surgical planning software that enables preoperative simulation and the Excelsius3D imaging module that provides intra operative visualization. Additional products are the ExcelsiusHub and ExcelsiusFlex accessories and the ExcelsiusXR extended reality headset designed to improve surgical accuracy and reduce radiation exposure.

Globus Medical, Inc. holds a competitive position in the medical device industry alongside major rivals such as Medtronic DePuy Synthes Stryker Zimmer Biomet and Smith & Nephew as well as Alphatec Holdings Orthofix Integra LifeSciences ZimVie VB Spine and Boston Scientific. The company differentiates itself through an engineering driven approach rapid product development cycles and close collaboration with surgeons to introduce innovative solutions. Its diversified portfolio across musculoskeletal solutions and enabling technologies allows it to address a broad range of patient needs and capture opportunities in adjacent markets. Furthermore the firm leverages its global sales force and surgeon education programs to strengthen customer loyalty and maintain market share.

The company serves hospitals ambulatory surgery centers and physicians who perform spinal orthopedic and neurosurgical procedures. Its customer base also includes academic medical centers research institutions and specialty clinics that focus on spine orthopedics and neurosurgery. Geographically the majority of revenue comes from the United States with a growing presence in Europe, Asia Pacific, and Latin America. While specific customer names are not disclosed in the filing the firm emphasizes long term partnerships with health care providers to support procedural volume and product adoption.

Investment Thesis

▲ Bull case

Globus Medical is positioned to capitalize on a structural shift in the enabling technology business model, where the strategic pivot from outright robot sales to lease and rental agreements is not a headwind but a catalyst for recurring revenue growth. Management explicitly noted that while Q1 Enabling Technologies revenue came primarily from cash sales, the pipeline is shifting toward leases and rentals—a change they are intentionally incorporating into their 2026 revenue guidance. This model, though reducing upfront revenue recognition, drives higher long-term pull-through of implants, disposables, service, and case coverage, aligning with their goal to increase recurring revenue streams. The company’s ExcelsiusGPS platform remains differentiated by its ease of use, reliability, and seamless workflow integration, with nearly 130,000 robotic procedures performed to date and no competitive system replicating its attributes. This entrenched position, combined with a flexible capital approach, allows Globus to expand its installed base faster in a competitive CapEx environment, turning what could be perceived as a revenue drag into a durable engine for implant-driven growth and customer stickiness.
The recent FDA 510(k) clearances for the Scripps patient-specific lumbar interbody spacer and rod system represent an underappreciated near-term catalyst that management did not heavily promote during the call but could significantly accelerate share gains in the lumbar fusion market. Scripps technology enables surgeons to design patient-matched implants using Scripps Studio software, which integrates directly with ExcelsiusGPS, Excelsius Hub, and ExcelsiusXR for robotically navigated placement. This creates a unique, end-to-end offering where Globus is the only company providing a complete portfolio of patient-specific lumbar interbody spacers and rods integrated with its enabling technology platform. By minimizing nerve retraction through lower-height insertion and expanding to restore optimal disc height, the system addresses unmet clinical needs in complex spine procedures. The bundle with high-quality implants, disc prep, retractor systems, and Excelsius suite ensures final placement matches the digital pre-op plan, enhancing surgical precision and outcomes. This innovation strengthens Globus’s moat in enabling technology and positions it to capture premium pricing and surgeon loyalty in a high-growth segment of spine surgery.
Globus’s disciplined capital allocation and operational execution are creating a self-reinforcing cycle of margin expansion and shareholder returns that the market may be underestimating. The company has maintained a 69.2% adjusted gross profit margin in Q1 2026 despite the typical sequential step-down from Q4, signaling that manufacturing and supply chain initiatives are delivering durable cost savings rather than temporary benefits. With a long-term target of mid-70s adjusted gross margin and a clear path to achieve it through fixed-cost leverage, favorable sales mix, and synergy execution, Globus is poised for sustained profitability expansion. This is amplified by its aggressive share repurchase program—having bought back over 10 million shares at under $60 average price since 2022, representing over 25% of the dilution from the NuVasive merger—while remaining debt-free and generating significant free cash flow. The combination of margin expansion, earnings growth (non-GAAP EPS up 64.7% YoY in Q1), and capital returns creates a powerful compounding effect that supports the raised 2026 non-GAAP EPS guidance of $4.70–$4.80, implying 18.1%–20.6% YoY growth.

Globus Medical is positioned to capitalize on a structural shift in the enabling technology business model, where the strategic pivot from outright robot sales to lease and rental agreements is not a headwind but a catalyst for recurring revenue growth. Management explicitly noted that while Q1 Enabling Technologies revenue came primarily from cash sales, the pipeline is shifting toward leases and rentals—a change they are intentionally incorporating into their 2026 revenue guidance. This model, though reducing upfront revenue recognition, drives higher long-term pull-through of implants, disposables, service, and case coverage, aligning with their goal to increase recurring revenue streams. The company’s ExcelsiusGPS platform remains differentiated by its ease of use, reliability, and seamless workflow integration, with nearly 130,000 robotic procedures performed to date and no competitive system replicating its attributes. This entrenched position, combined with a flexible capital approach, allows Globus to expand its installed base faster in a competitive CapEx environment, turning what could be perceived as a revenue drag into a durable engine for implant-driven growth and customer stickiness.
The recent FDA 510(k) clearances for the Scripps patient-specific lumbar interbody spacer and rod system represent an underappreciated near-term catalyst that management did not heavily promote during the call but could significantly accelerate share gains in the lumbar fusion market. Scripps technology enables surgeons to design patient-matched implants using Scripps Studio software, which integrates directly with ExcelsiusGPS, Excelsius Hub, and ExcelsiusXR for robotically navigated placement. This creates a unique, end-to-end offering where Globus is the only company providing a complete portfolio of patient-specific lumbar interbody spacers and rods integrated with its enabling technology platform. By minimizing nerve retraction through lower-height insertion and expanding to restore optimal disc height, the system addresses unmet clinical needs in complex spine procedures. The bundle with high-quality implants, disc prep, retractor systems, and Excelsius suite ensures final placement matches the digital pre-op plan, enhancing surgical precision and outcomes. This innovation strengthens Globus’s moat in enabling technology and positions it to capture premium pricing and surgeon loyalty in a high-growth segment of spine surgery.
Globus’s disciplined capital allocation and operational execution are creating a self-reinforcing cycle of margin expansion and shareholder returns that the market may be underestimating. The company has maintained a 69.2% adjusted gross profit margin in Q1 2026 despite the typical sequential step-down from Q4, signaling that manufacturing and supply chain initiatives are delivering durable cost savings rather than temporary benefits. With a long-term target of mid-70s adjusted gross margin and a clear path to achieve it through fixed-cost leverage, favorable sales mix, and synergy execution, Globus is poised for sustained profitability expansion. This is amplified by its aggressive share repurchase program—having bought back over 10 million shares at under $60 average price since 2022, representing over 25% of the dilution from the NuVasive merger—while remaining debt-free and generating significant free cash flow. The combination of margin expansion, earnings growth (non-GAAP EPS up 64.7% YoY in Q1), and capital returns creates a powerful compounding effect that supports the raised 2026 non-GAAP EPS guidance of $4.70–$4.80, implying 18.1%–20.6% YoY growth.

▼ Bear case

Globus Medical’s reliance on share gains as the primary driver of U.S. Spine growth—acknowledged by Keith Pfeil as the source of “the majority” of its 10% U.S. Spine growth—masks underlying market weakness and raises concerns about the sustainability of its outperformance. While management estimates the underlying spine market is growing only 3% to 3.5%, Globus’s double-digit growth implies it is taking share aggressively, a strategy that may become increasingly difficult as competitors like Medtronic enhance their offerings and hospitals demand more competitive evaluations, elongating sales cycles. The company’s competitive recruiting strategy, while cited as a moat, requires continuous investment in rep onboarding, sets, and inventories, risks diminishing returns if market share gains plateau. Furthermore, the shift in Enabling Technologies toward lease and rental models, while strategically sound, introduces revenue lumpiness and delays in upfront recognition, which could obscure true growth trends and make it harder for investors to assess the health of the core robotics business, especially if adoption slows amid rising competition.
The Nevro integration continues to pose execution risks that management downplayed despite clear sequential revenue declines and ongoing restructuring efforts. Nevro contributed $82.7 million in Q1 2026 revenue, down $17.1 million sequentially from Q4 2025—a 17.1% drop attributed to structural changes in sales and marketing made at the tail end of 2025. While Kyle Kline framed this as anticipated “lumpiness” and expressed confidence in a return to historical run rates later in 2026, the lack of transparency around Nevro’s pre-acquisition baseline (withholding Q1 2025 results) and the admission that the business may “get a little bit worse before it gets better” suggest near-term volatility. The business remains under pressure to adopt Globus’s profitable sales model, with SG&A consuming 55.7% of Nevro sales versus 37.2% for base Globus, indicating significant inefficiencies. Until Nevro demonstrates consistent profitability and revenue stability, it remains a drag on consolidated margins and a potential distraction from core spine and trauma growth initiatives.
Globus’s long-term gross margin expansion thesis faces headwinds from pricing pressure in a increasingly competitive spine market, despite management’s emphasis on cost control as the primary lever. Keith Pfeil acknowledged that new product launches typically come with a 1% price erosion headwind, and while the company aims to offset this through premium pricing on differentiated offerings like Scripps, the reality is that hospitals and GPOs are exerting greater scrutiny on pricing, particularly as robotic platforms and patient-specific implants become more commoditized over time. The company’s goal of achieving mid-70s adjusted gross margins relies heavily on manufacturing and supply chain efficiencies, but these gains may be offset by rising input costs, wage inflation, and the need for continued R&D investment—projected to increase to 5%–6% of sales in 2026 from 4.8% in Q1—to sustain its innovation pipeline. Without meaningful pricing power, margin expansion could stall, making the path to mid-70s gross margins more gradual and less certain than implied by the current guidance uplift.

Globus Medical’s reliance on share gains as the primary driver of U.S. Spine growth—acknowledged by Keith Pfeil as the source of “the majority” of its 10% U.S. Spine growth—masks underlying market weakness and raises concerns about the sustainability of its outperformance. While management estimates the underlying spine market is growing only 3% to 3.5%, Globus’s double-digit growth implies it is taking share aggressively, a strategy that may become increasingly difficult as competitors like Medtronic enhance their offerings and hospitals demand more competitive evaluations, elongating sales cycles. The company’s competitive recruiting strategy, while cited as a moat, requires continuous investment in rep onboarding, sets, and inventories, risks diminishing returns if market share gains plateau. Furthermore, the shift in Enabling Technologies toward lease and rental models, while strategically sound, introduces revenue lumpiness and delays in upfront recognition, which could obscure true growth trends and make it harder for investors to assess the health of the core robotics business, especially if adoption slows amid rising competition.
The Nevro integration continues to pose execution risks that management downplayed despite clear sequential revenue declines and ongoing restructuring efforts. Nevro contributed $82.7 million in Q1 2026 revenue, down $17.1 million sequentially from Q4 2025—a 17.1% drop attributed to structural changes in sales and marketing made at the tail end of 2025. While Kyle Kline framed this as anticipated “lumpiness” and expressed confidence in a return to historical run rates later in 2026, the lack of transparency around Nevro’s pre-acquisition baseline (withholding Q1 2025 results) and the admission that the business may “get a little bit worse before it gets better” suggest near-term volatility. The business remains under pressure to adopt Globus’s profitable sales model, with SG&A consuming 55.7% of Nevro sales versus 37.2% for base Globus, indicating significant inefficiencies. Until Nevro demonstrates consistent profitability and revenue stability, it remains a drag on consolidated margins and a potential distraction from core spine and trauma growth initiatives.
Globus’s long-term gross margin expansion thesis faces headwinds from pricing pressure in a increasingly competitive spine market, despite management’s emphasis on cost control as the primary lever. Keith Pfeil acknowledged that new product launches typically come with a 1% price erosion headwind, and while the company aims to offset this through premium pricing on differentiated offerings like Scripps, the reality is that hospitals and GPOs are exerting greater scrutiny on pricing, particularly as robotic platforms and patient-specific implants become more commoditized over time. The company’s goal of achieving mid-70s adjusted gross margins relies heavily on manufacturing and supply chain efficiencies, but these gains may be offset by rising input costs, wage inflation, and the need for continued R&D investment—projected to increase to 5%–6% of sales in 2026 from 4.8% in Q1—to sustain its innovation pipeline. Without meaningful pricing power, margin expansion could stall, making the path to mid-70s gross margins more gradual and less certain than implied by the current guidance uplift.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password